CUMBERLAND, RI-- (BUSINESS WIRE)— January 4, 2005—Collegium Pharmaceutical, Inc., a specialty pharmaceutical product development company, and HEALTHPOINT^®, Ltd. a leader in the research, development, and marketing of branded pharmaceuticals for tissue management, dermatology and surgical applications today announced that they have entered into a Licensing Agreement for the commercialization of two of Collegium’s topical analgesic products. Collegium developed each of the products and will remain responsible for all pre-launch activities including coordinating manufacturing of the launch quantities of  products. 

A patent application has been filed by Collegium that covers both products.  The patent is currently pending. 

HEALTHPOINT’s marketing team and sales force will be responsible for the commercial launch and all subsequent post-launch activities for both products. 

The companies expect that the first product will launch in the first half of 2005.

“We are very pleased to have entered into this agreement with HEALTHPOINT. Based upon our research, HEALTHPOINT is an exceptional partner to commercialize these products and has an excellent reputation in the market.  We believe HEALTHPOINT will be able to maximize the potential for these two important patent pending products that will offer potential clinical advantages over currently available formulations” said Michael Heffernan, President of Collegium. 

Collegium’s business model is to develop differentiated, patent protected products with enhanced clinical profiles, take them through “proof of concept” studies and then out-license the products for commercialization by a strategic marketing partner. 

“This agreement is HEALTHPOINT’s first major step in strategically expanding our surgical business unit from a product portfolio of innovative skin asepsis products into unique pharmaceutical solutions for surgical procedures that focus on skin and soft tissue and improve patient outcomes,” said Paul Duesterhoft, Vice President, HEALTHPOINT Surgical.    

“Working with Collegium will be a good fit for HEALTHPOINT,” continued Mr. Duesterhoft.  “In seeking a partner, we were impressed with the development capabilities, strategies, products and business model of Collegium. We believe that this will prove to be a successful agreement both now and as we look towards the future.”   

Collegium will be paid certain milestones in addition to royalties on the sales of the products.  

About HEALTHPOINT LTD
Since its inception in 1992, HEALTHPOINT has established a  presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and surgical indications.  An aggressive research and development effort has brought HEALTHPOINT’s unique technologies to the market, setting the pace for its highly trained field sales organization of direct sales representatives.  HEALTHPOINT, with over 300 employees, is a DFB Pharmaceuticals, Inc. affiliate company.  HEALTHPOINT is based in Fort Worth, Texas.  Visit HEALTHPOINT’s web site at www.healthpoint.com. 

Also headquartered in Fort Worth, DFB Pharmaceuticals, Inc.,  provides technology-driven products, outsourcing services, and licensing opportunities to the healthcare industry worldwide through its affiliate companies, contract partners, and branded marketing organizations.

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., is a privately held pharmaceutical company focused on the development of proprietary, late stage pharmaceutical products. These products target market opportunities through product enhancements and line extension strategies protected by intellectual property (IP).  Collegium applies customized pharmaceutical formulations and IP strategies to drugs that are safe and effective, creating a portfolio of improved pharmaceutical products with potentially less development risk and shorter times to market.  Collegium uses its broad expertise in IP development, drug formulation, manufacturing, basic science (chemistry, biology, bioengineering), marketing and clinical trials management to identify and execute product opportunities for itself and its partners.  For more information, visit the Company’s website at www.collegiumpharma.com.